Regulus Therapeutics Inc

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.